Rahul K. Mannan

Rahul K. Mannan

Obstetrics and Gynecology
447 McAlister Road
Suite 3500
Lincolnton, NC 28092

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 96 publications

Combined BET bromodomain and DNMT inhibition targets critical survival pathways in transdifferentiated prostate cancer.

Combined BET bromodomain and DNMT inhibition targets critical survival pathways in transdifferentiated prostate cancer.

Journal: JCI insight
Published: August 11, 2026

NNMT Loss Drives Cancer Progression by enhancing SAM availability for mTORC1 Signaling and Chromatin Methylation.

NNMT Loss Drives Cancer Progression by enhancing SAM availability for mTORC1 Signaling and Chromatin Methylation.

Journal: bioRxiv : the preprint server for biology
Published: August 05, 2026

A Stress-Adaptive Lipid Kinase Axis Defines Metabolic Vulnerabilities in Neuroendocrine Prostate Cancer.

A Stress-Adaptive Lipid Kinase Axis Defines Metabolic Vulnerabilities in Neuroendocrine Prostate Cancer.

Journal: bioRxiv : the preprint server for biology
Published: July 30, 2026

A ligandable PNT domain establishes ERG as a directly targetable oncogenic driver in prostate cancer.

A ligandable PNT domain establishes ERG as a directly targetable oncogenic driver in prostate cancer.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: July 07, 2026

A harmonized single-cell RNA-seq atlas of human localized and metastatic prostate cancers and benign tissues.

A harmonized single-cell RNA-seq atlas of human localized and metastatic prostate cancers and benign tissues.

Journal: bioRxiv : the preprint server for biology
Published: June 04, 2026

Rewiring Oncogenic Transcriptional Complexes with Domain-ALTeration Chimeras (DALTACs) in Prostate Cancer.

Rewiring Oncogenic Transcriptional Complexes with Domain-ALTeration Chimeras (DALTACs) in Prostate Cancer.

Journal: bioRxiv : the preprint server for biology
Published: May 07, 2026

Cellular cartography reveals mouse prostate organization and determinants of castration resistance.

Cellular cartography reveals mouse prostate organization and determinants of castration resistance.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: August 25, 2025

A stress-adaptive lipid kinase axis defines metabolic vulnerabilities in neuroendocrine prostate cancer.

A stress-adaptive lipid kinase axis defines metabolic vulnerabilities in neuroendocrine prostate cancer.

Journal: Cancer cell
Published: August 13, 2025

Divergent FOXA1 mutations drive prostate tumorigenesis and therapy-resistant cellular plasticity.

Divergent FOXA1 mutations drive prostate tumorigenesis and therapy-resistant cellular plasticity.

Journal: Science (New York, N.Y.)
Published: June 26, 2025

Defining CDK12 as a tumor suppressor and therapeutic target in mouse models of tubo-ovarian high-grade serous carcinoma.

Defining CDK12 as a tumor suppressor and therapeutic target in mouse models of tubo-ovarian high-grade serous carcinoma.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: June 12, 2025

Targeting the ferritinophagy-lysosome axis as a therapeutic vulnerability in gastroenteropancreatic neuroendocrine tumors.

Targeting the ferritinophagy-lysosome axis as a therapeutic vulnerability in gastroenteropancreatic neuroendocrine tumors.

Journal: Cell reports. Medicine
Published: May 29, 2025

A phase 2 multicenter trial of rucaparib and nivolumab as maintenance therapy in patients with advanced biliary tract cancer: BilT-02.

A phase 2 multicenter trial of rucaparib and nivolumab as maintenance therapy in patients with advanced biliary tract cancer: BilT-02.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 29, 2025
Showing 1-12 of 96

Last Updated: 09/26/2026